Teduglutide in Crohn's disease

Bibliography

• Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29
   PubMed Web of Science ®Google Scholar
• Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 1986;105:883-5
   PubMed Web of Science ®Google Scholar
• Buhner S, Buning C, Genschel J, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut 2006;55:342-7
   PubMed Web of Science ®Google Scholar
• D'Inca R, Annese V, di Leo V, et al. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment Pharmacol Ther 2006;23:1455-61
   PubMed Web of Science ®Google Scholar
• D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7
   PubMed Web of Science ®Google Scholar
• Guan X, Karpen HE, Stephens J, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006;130:150-64
   PubMed Web of Science ®Google Scholar
• Wojdemann M, Wettergren A, Hartmann B, et al. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998;33:828-32
   PubMed Web of Science ®Google Scholar
• Wojdemann M, Wettergren A, Hartmann B, et al. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999;84:2513-17
   PubMed Web of Science ®Google Scholar
• Guan X, Stoll B, Lu X, et al. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 2003;125:136-47
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Erlich P, Asa SL, et al. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996;93:7911-16
   PubMed Web of Science ®Google Scholar
• Tsai CH, Hill M, Asa SL, et al. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol 1997;273:E77-84
   PubMed Web of Science ®Google Scholar
• Shin ED, Estall JL, Izzo A, et al. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 2005;128:1340-53
   PubMed Web of Science ®Google Scholar
• Litvak DA, Hellmich MR, Evers BM, et al. Glucagon-like peptide 2 is a potent growth factor for small intestine and colon. J Gastrointest Surg 1998;2:146-50
   PubMedGoogle Scholar
• Kouris GJ, Liu Q, Rossi H, et al. The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis. Am J Surg 2001;181:571-5
   PubMed Web of Science ®Google Scholar
• Benjamin MA, McKay DM, Yang PC, et al. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000;47:112-19
   PubMed Web of Science ®Google Scholar
• Teduglutide prescribing information. NPS pharmaceuticals, Bedminster, NJ, USA; 2012
   Google Scholar
• Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001;120:806-15
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005;54:1224-31
   PubMed Web of Science ®Google Scholar
• Marier JF, Beliveau M, Mouksassi MS, et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol 2008;48:1289-99
   PubMed Web of Science ®Google Scholar
• Marier JF, Mouksassi MS, Gosselin NH, et al. Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. J Clin Pharmacol 2010;50:36-49
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011;60:902-14
   PubMed Web of Science ®Google Scholar
• O'Keefe SJ, Jeppesen PB, Gilroy R, et al. Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure. Clin Gastroenterol Hepatol 2013; Epub ahead of print
   Google Scholar
• Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 2012;143:1473-81. e3
   PubMed Web of Science ®Google Scholar
• Buchman AL, Katz S, Fang JC, et al. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 2010;16:962-73
   PubMed Web of Science ®Google Scholar
• Crenn P, Coudray-Lucas C, Thuillier F, et al. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 2000;119:1496-505
   PubMed Web of Science ®Google Scholar
• Crenn P, Vahedi K, Lavergne-Slove A, et al. Plasma citrulline: a marker of enterocyte mass in villous atrophy-associated small bowel disease. Gastroenterology 2003;124:1210-19
   PubMed Web of Science ®Google Scholar
• Gondolesi G, Ghirardo S, Raymond K, et al. The value of plasma citrulline to predict mucosal injury in intestinal allografts. Am J Transplant 2006;6:2786-90
   PubMed Web of Science ®Google Scholar
• FDA approves Gattex to treat short bowel syndrome. FDA NEWS RELEASE Washington, DC. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333171.htm [Last accessed 5 January 2013]
   Google Scholar
• Alters SE, McLaughlin B, Spink B, et al. GLP2-2G-XTEN: a Pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model. PLoS One 2012;7:e50630
   PubMed Web of Science ®Google Scholar